Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GlycoMimetics, Inc. - Common Stock (NQ: GLYC )

0.2637 +0.0041 (+1.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 Next >
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
From GlycoMimetics, Inc.
Via Business Wire
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE - ARC)
From Brodsky & Smith LLC
Via GlobeNewswire
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.